Navigation Links
Biodel to Provide Update on Stabilized Glucagon Program at ROTH Conference Today
Date:3/14/2012

ts to differ materially from those described or implied in the forward-looking statements, including, but not limited to, the success of our product candidates, particularly our proprietary formulations of injectable insulin that are designed to be absorbed more rapidly than the "rapid-acting" mealtime insulin analogs presently used to treat patients with Type 1 and Type 2 diabetes; our ability to conduct pivotal clinical trials, other tests or analyses required by the U.S. Food and Drug Administration, or FDA, to secure approval to commercialize a proprietary formulation of injectable insulin; our ability to secure approval from the FDA for our product candidates under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act; the progress, timing or success of our research, development and clinical programs, including any resulting data analyses; our ability to develop and commercialize a proprietary formulation of injectable insulin that may be associated with less injection site discomfort than Linjeta™ (formerly referred to as VIAject®), which is the subject of a complete response letter we received from the FDA; our ability to enter into collaboration arrangements for the commercialization of our product candidates and the success or failure of any such collaborations into which we enter, or our ability to commercialize our product candidates ourselves; our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; the degree of clinical utility of our product candidates; the ability of our major suppliers to produce our products in our final dosage form; our commercialization, marketing and manufacturing capabilities and strategies; our ability to accurately estimate anticipated operating losses, future revenues, capital requirements and our needs for additional financing; and other factors identified in our most recent report on Form 10-Q for the quarter ended Decem
'/>"/>
SOURCE Biodel Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Federal Court Grants Request by BioDelivery Sciences for Stay of MonoSol Litigation
2. Biodel Inc. to Present at ROTH 24th Annual OC Growth Stock Conference on March 14th, 2012
3. US Patent Office Rejection of All Claims in Final Asserted MonoSol Patent Further Supports BioDelivery Sciences Position
4. BioDelivery Sciences and FDA Reach Agreement on BNX Development Plan
5. Biodel Inc. to Present at 30th Annual JPMorgan Healthcare Conference on January 12th, 2012
6. Endo Pharmaceuticals and BioDelivery Sciences International Sign Licensing Agreement for BEMA Buprenorphine
7. BioDelivery Sciences Announces Worldwide License and Development Agreement with Endo Pharmaceuticals for BEMA Buprenorphine
8. BioDelivery Sciences Announces Confirmation of Final Formulation of BEMA Buprenorphine/Naloxone Based on Positive BNX-102 Study
9. Biodel to Report Fourth Quarter Fiscal Year 2011 Financial Results on December 6, 2011
10. BioDelivery Sciences to Host Business Update Webcast and Conference Call on Tuesday, November 15, 2011 at 8:30 AM Eastern Time
11. BioDelivery Sciences Initiates Confirmatory Pharmacokinetic Study of BEMA Buprenorphine/Naloxone Compared to Suboxone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014 Moms are ready ... trackers for themselves and their kids, according to the ... Health & Fitness Go Mobile for Moms, the latest ... BabyCenter, the number 1 pregnancy and parenting web and ... 55 percent of moms surveyed say they can,t think ...
(Date:10/22/2014)... A new report by Allied ... Form, End user, Application and Geography) - Size, Share, ... Opportunities, Segmentation and Forecast, 2013 - 2020", considers commercial ... key trends tracked, it is anticipated that the market ... 2020, registering a CAGR of 6.2% from 2014 to ...
(Date:10/22/2014)... 22, 2014 Oramed Pharmaceuticals ... clinical-stage pharmaceutical company focused on the development of ... clinical results from its Phase IIa clinical trial ... to treat type 1 diabetes. The trial was conducted ... under a U.S. Food and Drug Administration (FDA) ...
Breaking Medicine Technology:BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 2BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 3BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 4Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4
(Date:10/22/2014)... With the Affordable Care Act (ACA) open enrollment ... Institutes for Research (AIR) finds that three out of four ... but 42 percent say they are not likely or only ... for coverage. , The AIR survey found wide gaps in ... calculate correctly how much they owe for a routine doctor’s ...
(Date:10/22/2014)... Best Cheap Hosting USA is among the most distinguished ... announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) is the best ... world. , “iPower is one of the most reliable ... kinds of useful products for new and old clients. ... service and a number of features which will appeal ...
(Date:10/22/2014)... 22, 2014 Losing Weight Your Body’s Way ... staring you in the face, it certainly can be difficult ... your body an extra favor by doing it the healthy ... diets. Instead, listen to your body, exercise regularly, and choose ... essential to losing weight; you need to exercise more and ...
(Date:10/22/2014)... Lintelus, Inc., an event software provider, announced ... will be speaking on the subject of “Event Technology ... 28, at the Holiday Inn in New York City. ... as a Tech Demo at 12:45pm, to educate event ... engaging event experience. , The Annual Meetings Technology Expo ...
(Date:10/22/2014)... MA (PRWEB) October 22, 2014 ... new solutions for the treatment of bacterial infections, microbial ... Sinskey has joined its board of directors. , ... and Engineering Systems at The Massachusetts Institute of Technology, ... MIT faculty since 1968. Dr. Sinskey also holds positions ...
Breaking Medicine News(10 mins):Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2
... A new Dutch study contradicts the popular belief that ... a profound impact on the soldier’s partner and children//. ... on in any significant way. ,Psychiatrist Arend ... there is no scientific basis to the theory that ...
... Dallas and the Baylor Research Institute have developed a ... , ,Insulin is a hormone that allows ... the body to be used for energy. The technique, ... insulin genes to the organ via microscopic "bubbles." Once ...
... the Internet, cancer patients find it hard to locate ... new study has found. Surprisingly, most cancer patients seek ... cancer information on their own, reveals the study conducted ... ,Despite the ease and availability of Internet ...
... death toll in the fake drug case in China has ... on pharmaceutical companies//, the state media reported today. ... Armillarisni A injection made by the Qiqihar No 2 Pharmaceutical ... Sun Yat-sen University in South China's Guangdong Province. ...
... revealed that most of these survivors remain unemployed and the ... history of childhood cancer. ,Among the types of ... central nervous system tumors run a risk five times more ... blood-cell and bone marrow cancers, stood a far greater risk ...
... researchers from the University of Manchester feel that Statins, A ... UK// so as to effectively reduce the heart diseases. ... 65 from the mid-1980s to the mid-1990s, and recorded how ... then used the findings to calculate as to how many ...
Cached Medicine News:Health News:Bubble Technique on the cards For Treatment of Type I diabetes 2Health News:Internet Searches Fail To Give Useful Information To Cancer Patients 2Health News:A New Study Feels That The UK heart drug Guidelines Not Enough 2
Dilator...
Microscopic needle holder, curved...
Made with navy nylon reinforced vinyl for superior strength and ease of cleaning. Optional colors available are teal, royal, red, purple, and maroon nylon stain resistant material....
This apron was designed by Pulse Medical-RCI for optimal protection. Your comfort is also a primary concern so a wide support belt and shoulder pads are standard. When properly fitted, an overlapping...
Medicine Products: